H. Jack West

lung cancer nsclc egfr mutation cancer afatinib erlotinib acquired resistance oncology avastin crizotinib tarceva egfr bevacizumab non-small cell lung cancer ceritinib xalkori gefitinib t790m alk rearrangement immune checkpoint inhibitor genomic testing ramucirumab azd9291 sclc maintenance therapy chemotherapy local therapy iressa targeted therapy gilotrif c-met tivantinib taxotere dll3 adjuvant therapy lmwh avelumab taxol immunotherapy nedroparin paclitaxel small cell lung cancer antibody-drug conjugate low molecular weight heparin rova-t genomics next generation sequencing cancer genetics personalized medicine precision medicine low dose chest ct screening ldct nintedinib ngs exon 19 co-1686 exon 21 l858r del 19 bevacizumab/erlotinib necitumumab thoracic radiation therapy co1686 prophylactic cranial irradiation pemetrexed zykadia alimta multidisciplinary chemo/radiation surgery radiation locally advanced nsclc stage iii nsclc stage 3 locally advanced stage iv lung cancer advanced nsclc cancer progression response assessment disease progression grace germline mutation ct screening somatic mutation lung cancer risk side effects evolution adaptation resistance no evidence of disease advanced cancer micrometastases systemic therapy metastatic cancer ned social media cancer care patient groups engaged patients e-patients online patient communities cetuximab erbitux ldk378 alectinib alk metmab tki egfr inhibitor bibw-2992 arq-197 molecular oncology molecular testing eml4-alk nonprofit medicine 2.0